Locations:
Search IconSearch
November 18, 2016/Cancer/News & Insight

ASTRO Releases New APBI Guidelines: What Clinicians Need to Know (Video)

Key takeaways of the evidence-based consensus statement

Accelerated partial breast irradiation (APBI) allows appropriately selected patients with early-stage breast cancer to complete adjuvant radiation in one week or less following breast conserving surgery. To date, multiple randomized trials have demonstrated no difference in rates of recurrence or survival with APBI delivered using brachytherapy or external beam radiation techniques.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this video, Cleveland Clinic radiation oncologist Chirag Shah, MD, discusses the American Society of Radiation Oncology’s newly released updated guidelines for the off-protocol use of APBI. Most significantly, the guidelines lower the age cut-off from age 60 and older to age 50 and older, as well as include patients with ductal carcinoma in citu (low/intermediate grade, < 2.5 cm, negative surgical margins).

Dr. Shah also explains that suitable candidates for APBI include those 50 years or older with tumors < 3.0 cm, with negative margins, and that are estrogen receptor positive. With respect to intraoperative radiation (IORT), the new guidelines recommend counseling that IORT is associated with higher rates of local recurrence and that electron IORT be limited to only suitable APBI patients, while low-energy X-ray IORT should be limited to prospective registries or clinical trials.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650&#215;450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad